Straight explanations of the peptides we work with, the labs behind them, and the regulations that shape what's actually legal — written by the same team that reviews your panel.
A straight answer on BPC-157 — why we require labs first, and how the FDA advisory committee's July 2026 vote affects its compounding status.
Read the PostFDA Pharmacy Compounding Advisory Committee votes favorably on BPC-157 and five other peptides, July 23–24, 2026.
Why we require labs before it's ever part of a protocol, and what the FDA advisory committee's favorable vote means for its legal compounding status.
Read MoreThe shortage is over — here's what that actually changed, what's still legal under 503A, and what the April 2026 FDA proposal means for you.
Read MoreIt's not a formality — it's the baseline every future retest gets measured against.
Read MoreAll three share the same recovery foundation. Here's what GHK-Cu and KPV actually add, and how to think about which stack fits.
Read MoreWe're adding to this library regularly — check back, or follow @FLAPeptides for updates when a new post goes live.
